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Abstract
Aims To determine the prevalence and clinical characteristics of absolute insulin deficiency in long-standing Type 2
diabetes, using a strategy based on home urinary C-peptide creatinine ratio measurement.
Methods We assessed the urinary C-peptide creatinine ratios, from urine samples taken at home 2 h after the largest
meal of the day, in 191 insulin-treated subjects with Type 2 diabetes (diagnosis age ≥45 years, no insulin in the first
year). If the initial urinary C-peptide creatinine ratio was ≤0.2 nmol/mmol (representing absolute insulin deficiency), the
assessment was repeated. A standardized mixed-meal tolerance test with 90-min stimulated serum C-peptide
measurement was performed in nine subjects with a urinary C-peptide creatinine ratio ≤ 0.2 nmol/mmol (and in nine
controls with a urinary C-peptide creatinine ratio >0.2 nmol/mmol) to confirm absolute insulin deficiency.
Results A total of 2.7% of participants had absolute insulin deficiency confirmed by a mixed-meal tolerance test. They
were identified initially using urinary C-peptide creatinine ratio: 11/191 subjects (5.8%) had two consistent urinary
C-peptide creatinine ratios ≤ 0.2 nmol/mmol; 9 of these 11 subjects completed a mixed-meal tolerance test and had a
median stimulated serum C-peptide of 0.18 nmol/l. Five of these 9 had stimulated serum C-peptide <0.2 nmol/l and 9/9
subjects with urinary C-peptide creatinine ratio >0.2 had endogenous insulin secretion confirmed by the mixed-meal
tolerance test. Compared with subjects with a urinary C-peptide creatinine ratio >0.2 nmol/mmol, those with confirmed
absolute insulin deficiency had a shorter time to insulin treatment (median 2.5 vs. 6 years, P=0.005) and lower BMI
(25.1 vs. 29.1 kg/m2, P=0.04). Two out of the five patients with absolute insulin deficiency were glutamic acid
decarboxylase autoantibody-positive.
Conclusions Absolute insulin deficiency may occur in long-standing Type 2 diabetes, and cannot be reliably predicted
by clinical features or autoantibodies. Absolute insulin deficiency in Type 2 diabetes may increase the risk of
hypoglycaemia and ketoacidosis, as in Type 1 diabetes. Its recognition should help guide treatment, education and
management. The urinary C-peptide creatinine ratio is a practical non-invasive method to aid detection of absolute
insulin deficiency, with a urinary C-peptide creatinine ratio > 0.2 nmol/mmol being a reliable indicator of retained
endogenous insulin secretion.
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Introduction
Most older patients with diabetes have Type 2 diabetes,
which is typically a disease where endogenous insulin
persists. Progressive b-cell dysfunction occurs in Type 2
diabetes [1–4], but it is unclear if this leads to absolute
insulin deficiency. By contrast, in Type 1 diabetes absolute
insulin deficiency is usual outside the initial ‘honeymoon
period’, the period soon after diagnosis when some residual
b-cell function may persist [5].
Some patients may present clinically later in life as having
Type 2 diabetes, but have the autoimmune destructive
process as seen in Type 1 diabetes. These patients can be
recognised by pancreatic autoantibodies, known as latent
autoimmune diabetes of adulthood (LADA) [6]. People with
LADA may develop absolute insulin deficiency [7–10]. In
practice, however, autoantibody levels are rarely measured in
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patients presenting with adult-onset diabetes: a clinical
diagnosis of Type 2 diabetes is usually made and seldom
revisited, and so later subsequent development of absolute
insulin deficiency is rarely suspected or tested for.
Absolute insulin deficiency in patients with Type 2
diabetes is likely to carry similar risks to those associated
with Type 1 diabetes, such as fluctuant blood glucose levels,
high hypoglycaemia risk and diabetic ketoacidosis [11]. The
patient with Type 2 diabetes, however, is unlikely to be
offered a similar level of education to deal adequately with
these, such as the Dose Adjustment for Normal Eating
(DAFNE) programme [12]. Frail older people, in particular,
may be ill-equipped to cope with such complications, with
less functional reserve both physically and cognitively, and in
terms of their social support. The development of absolute
insulin deficiency in Type 2 diabetes will alter treatment: oral
hypoglycaemic agents (especially sulphonylureas) will not be
effective, the newer agents, e.g. glucagon-like peptide (GLP)-
1 receptor analogues and dipeptidyl peptidase (DPP)4
inhibitors, are not suitable, and the most appropriate insulin
regimen may be basal-bolus rather than background long-
acting insulin. With an estimated 870 000 people with
insulin-treated Type 2 diabetes in the UK, the development
of absolute insulin deficiency in even a small proportion
could have significant impact on both individuals and
society.
Endogenous insulin levels are rarely measured in routine
clinical practice, even in secondary care, owing to practical
limitations, including the need for rapid laboratory analysis
of blood tests. The majority of patients with Type 2 diabetes
are cared for in primary care where this is even less practical.
Recently, a simple urine test, the urinary C-peptide creatinine
ratio (UCPCR) [13], has been shown both in Type 1 diabetes
and Type 2 diabetes, to be excellently correlated with the
‘gold standard’ measure of endogenous insulin secretion, the
formal mixed-meal tolerance test (MMTT), and a sensitive
and specific test for absolute insulin deficiency [5,14]. The
UCPCR test has the advantages of being widely available,
and stable at room temperature for 3 days, so offering the
potential for widespread non-invasive testing which may be
particularly useful for a more frail, older population. The
aim of the present study was to use the UCPCR to test for
absolute insulin deficiency in older people with insulin-
treated Type 2 diabetes.
Methods
Subjects
A total of 191 insulin-treated subjects with Type 2 diabetes
(clinical diagnosis of Type 2 diabetes, diagnosis at ≥ 45 years
of age, insulin treatment not started within 1 year of
diagnosis) were recruited from primary care at the time of
their routine retinal screening appointment, and written
consent was obtained for participation in the study. Baseline
data collected included duration of diabetes, current treat-
ment, BMI and most recent HbA1c concentration.
Urine collection and analysis
Participants were asked to provide an initial urine sample,
collected at home, 2 h after their largest meal of the day. The
urine sample was collected in a standard mid-stream urine
boric acid-containing specimen pot, and returned by post to
the routine pathology laboratories for UCPCR analysis.
UCPCR ≤ 0.2 nmol/mmol is equivalent to a stimulated
serum C-peptide (sSCP) of 0.2 nmol/l in an MMTT [15,16],
representing an absence of clinically significant insulin
secretion [11]. This level is associated with unstable glyca-
emia, increased risk of hypoglycaemia and microvascular
complications (as well as absolute insulin requirement) in
Type 1 diabetes [11,16].
All patients identified as insulin-deficient were asked to
provide a repeat sample to confirm their initial result, as
were a random group of those with a UCPCR >0.2 nmol/
mmol.
Mixed-meal tolerance test
In those patients with consistent UCPCR results ≤0.2 nmol/
mmol, we performed a formal MMTT with their insulin
excluded, to confirm the absolute insulin deficiency [5].
A comparison group of age-matched participants with
UCPCR >0.2 nmol/mmol also underwent the standardized
MMTT [17]. In brief, subjects fasted from midnight, and
omitted their morning medications including insulin. Fasting
serum and urine samples were taken before participants
consumed 6 ml/kg Ensure Plus HP (Abbott Laboratories,
Abbott Park, IL, USA). A blood sample for sSCP was taken
90 min later, and a urine sample for UCPCR at 2 h. As
above, a sSCP concentration of <0.2 mmol/l was used to
represent absolute insulin deficiency [5,18].
Sample analysis
Urine and serum samples were analysed for C-peptide using
an electrochemiluminescence immunoassay (intra-assay coef-
ficient of variation <3.3%; interassay coefficient of variation
<4.5%) on a Roche Diagnostics E170 analyser (Roche,
Mannheim, Germany) by the biochemistry department at the
Royal Devon and Exeter NHS Foundation Trust. Urine
creatinine was analysed on the Roche P800 platform using
creatinine Jaffe reagent (standardized against isotope dilution
mass spectrometry) to obtain a urinary C-peptide creatinine
ratio. Blood samples for all patients completing the MMTT
were analysed for glutamic acid decarboxylase (GAD)65 and
islet antigen 2 (IA2) autoantibodies, using the Biokit auto-
mated Elisa System (BEST 2000; Biokit, Barcelona, Spain)
following the manufacturer’s instructions. The cut-offs used
were those based on the 99th centile for 500 individuals
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without diabetes; for GAD65 the reference-positive value
was >64 units/ml, for IA2 the reference-positive value was
>15 units/ml.
Data analysis
The data were not normally distributed, and so are presented
as medians and interquartile ranges (IQRs). Results
were analysed primarily by comparing the clinical charac-
teristics of those with confirmed absolute insulin deficiency
on MMTT and those with endogenous insulin secretion,
using Mann–Whitney U- and chi-squared tests (using
Predictive Analytic Software: PASW 17.0). The full group
of 167 participants with an initial home UCPCR >0.2 nmol/
mmol was used to represent those with significant insulin
secretion, given the consistency of repeat UCPCR and
MMTT results in subgroups drawn from these (see Results
and Fig. 1).
Ethics approval was obtained from the Southwest
Research Ethics Committee.
Results
A total of 191 participants, with a median (IQR) age 73.5
(67–78) years and of whom 37% were women, provided an
initial urine sample for UCPCR measurement. They had a
median (IQR) age at diagnosis of 58 (50–65) years, duration
of diabetes of 13.5 (9–19) years, and BMI at recruitment of
29 (25.9–33.54) kg/m2. Their median (IQR) time to insulin
treatment from diagnosis was 6 (3.5–11) years.
Figure 1 shows the flow of patients through the study. Of
the 191 participants screened, 24 (12.5%) had UCPCR ≤
0.2 nmol/mmol. Of these, 21 provided a repeat sample, and
11/188 (6% of the whole cohort) had two consistent UCPCR
results of ≤ 0.2 nmol/mmol.
Table 1 shows the MMTT results of the two groups
selected on the basis of their UCPCR. These two groups were
similar in age, duration of diabetes, time to insulin from
diagnosis, and BMI. As expected the sSCP concentration was
lower in those with a low UCPCR than in those with a high
UCPCR (median 0.18 vs. 2.0 nmol/l, respectively, P = 0.002).
Five of the nine participants with a low UCPCR had a sSCP of
<0.2 nmol/l, representing absolute insulin deficiency [18], in
contrast to none with a high UCPCR had a sSCP <0.2 nmol/l.
This suggests a minimum prevalence of absolute insulin
deficiency in insulin-treated Type 2 diabetes of 3% [5/186,
excluding the five subjects who were unable to provide repeat
urine samples or participate in the MMTT (Fig. 1)].
Notably, the UCPCR results obtained in both groups were
substantially higher after the MMTT than after the home
Insulin-treated subjects with Type 2 
diabetes, diagnosed ≥45 and started 
insulin treatment >12 months from 
diagnosis
UCPCR ≤0.2 nmol/mmol
n = 24
N = 191
UCPCR >0.2nmol/mmol
n = 167
n = 21
(three uncontactable)
n = 21
(to match ≤0.2 subgroup)
UCPCR >0.2nmol/mmol 
n = 10 
UCPCR ≤0.2nmol/mmol  
n = 11
UCPCR >0.2nmol/mmol
n = 21
UCPCR ≤0.2nmol/mmol 
n = 0
n = 9
(two unable to do MMTT)
n = 9
(matched to UCPCR <0.2)
sSCP ≤0.2nmol/L 
n = 5
sSCP >0.2nmol/L
n = 9
Home UCPCR
Repeat Home UCPCR
MMTT
FIGURE 1 Flow of participants through the study. UCPCR, urinary C-peptide creatinine ratio; MMTT, mixed-meal tolerance test; sSCP, stimulated
serum C-peptide.
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meal. For those four patients with two home UCPCRs ≤
0.2 nmol/mmol but an sSCP >0.2 nmol/l, the post-MMTT
UCPCR results were also >0.2 nmol/mmol. This suggests the
MMTT provided more b-cell stimulation than did the meals
consumed at home.
The five patients with confirmed absolute deficiency on
MMTT had a lower BMI (BMI 25.1 vs. 29.1 kg/m2,
P=0.04), and commenced insulin treatment more rapidly
after diagnosis (2.5 vs. 6 years, P=0.005), although there was
substantial overlap for both these measures between those
with (n=5) and without (n=167) absolute insulin deficiency.
There was no difference in age of diagnosis, duration of
diabetes, glycaemic control or insulin dose (Table 2).
Two of the five participants with absolute insulin defi-
ciency were GAD-positive (titre in both >2000 units/ml); one
of these was also IA2 positive (titre 74.9 units/ml). In
addition, one patient who had two low UCPCR measure-
ments from home but an sSCP of 0.37 nmol/l was GAD-
positive (titre >2000 units/ml). None of the nine participants
from the comparison MMTT group, i.e. with home UCPCR
demonstrating residual endogenous insulin secretion and
confirmed on MMTT, were positive for GAD or IA2
antibodies.
Notably, only two of the five participants with absolute
insulin deficiency were on a basal-bolus regimen, and two
were treated with oral agents in combination with insulin.
Discussion
A total of 2.7% of insulin-treated patients with a clinical
diagnosis of Type 2 diabetes in the present study were found
to have absolute insulin deficiency. Patients who may have
had absolute insulin deficiency were detected using the
simple non-invasive testing method, the UCPCR, and a
MMTT was used to confirm findings. These patients cannot
be solely identified on the basis of clinical characteristics, or
by testing of GAD antibodies.
Prevalence and aetiology of absolute insulin deficiency in
Type 2 diabetes
Our prevalence of absolute insulin deficiency of 2.7% (5/
186) is similar to the 2.3% (3/133) found at 10 years from
diagnosis in an observational study by Niskanen et al. [7].
This looked at adult patients over the age of 45 years with
new-onset non-insulin-dependent diabetes, and measured
sSCP and GAD titres at 0, 5 and 10 years. By including only
insulin-treated patients in our study, one might have
expected a more insulin-deficient group and hence a com-
paratively higher proportion of patients with absolute insulin
deficiency than in the study by Niskanen et al. The aim for
tighter glycaemic control (and hence earlier initiation of
insulin) in the post-Diabetes Control and Complications
Trial/United Kingdom Prospective Diabetes Study era may
provide an explanation for why this was not seen. Addition-
ally, the 2.7% prevalence in our study population is a
minimum: there were five additional participants with an
initial UCPCR suggestive of absolute insulin deficiency
who were either uncontactable or unable to undergo a
MMTT (Fig. 1). If all these participants had confirmed
sSCP <0.2 nmol/l, the prevalence would have risen to 5.2%
(10/191).
Table 1 Urinary C-peptide creatinine ratios and stimulated serum
C-peptide values in nine subjects with two home UCPCRs of
≤0.2 nmol/mmol, compared with nine matched subjects with two
home UCPCRs of >0.2 nmol/mmol
UCPCR ≤0.2
nmol/mmol
UCPCR >0.2
nmol/mmol P
UCPCR (home),
nmol/mmol
<0.02
(<0.02–0.2)
1.7
(0.8–7.1)
<0.001
UCPCR (MMTT)
nmol/mmol
0.07
(<0.02–0.7)
2.6
(1.9–5.6)
0.001
fSCP, nmol/l 0.13
(0.08–0.35)
0.59
(0.45–0.88)
0.003
sSCP, nmol/l 0.18
(0.08–0.64)
2.0
(1.53–2.52)
0.002
Data are shown as median values (interquartile range).
UCPCR, urinary C-peptide creatinine ratio; MMTT, mixed-
meal tolerance test; fSCP, fasting serum C-peptide; sSCP,
stimulated serum C-peptide.
Table 2 Clinical characteristics of those with absolute insulin
deficiency as confirmed by a mixed-meal tolerance test, vs those with
endogenous insulin secretion (urinary C-peptide creatinine ratio
>0.2 nmol/mmol)
Absolute
insulin
deficiency
Endogenous
insulin
secretion P
n 5 167
Age at diagnosis,
years
63 (54–72) 58 (50–66) 0.28
Duration of
diabetes, years
12 (9.5–19.5) 13 (9–17) 0.87
BMI, kg/m2 25.1 (22.8–28.8) 29.1 (26.3–33.6) 0.04
HbA1c,
mmol/mol
72 (57–85) 62 (55–69) 0.24
HbA1c,% 8.7 (7.4–9.9) 7.8 (7.2–8.5)
Time to
insulin from
diagnosis,
years
2.5 (1.5–3) 6 (3–10.75) 0.005
Insulin/kg/24 h,
units/kg/24 h
0.72 (0.54–0.88) 0.51 (0.31–0.84) 0.26
No. of subjects
on oral hypo-
glycaemic
agent, in
addition to
insulin (%)*
2/5 (40) 115/167 (69) 0.17
No. of subjects
on basal-bolus
regime (%)*†
2/5 (40) 19/167 (11) 0.05
Data shown as medians (interquartile range).
*Chi-squared tests; all others Mann–Whitney U-test. †Basal-
bolus regime: four or five injections of insulin a day.
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In subjects with high titres of GAD antibodies and
reasonably long diabetes duration (10–12 years), prospective
longitudinal studies have shown that many (but not all)
develop absolute insulin deficiency [7,9]. When combined
with the clinical features of adult-onset diabetes not
immediately requiring insulin treatment, the presence of
pancreatic autoantibodies is known as LADA [7,9,10].
Two of the five participants with absolute insulin defi-
ciency in our study fit these criteria, having high GAD titres
(>2000 units/ml, reference value >64 units/ml); however,
with three participants with a confirmed absolute insulin
deficiency not exhibiting GAD antibodies, it suggests that the
presence of these antibodies is not a sensitive test for
detecting the development of absolute insulin deficiency in
those with long-standing diabetes.
Our study has hence identified three people with apparent
non-autoimmune Type 2 diabetes and confirmed absolute
insulin deficiency. Of the three patients developing absolute
insulin deficiency in the study by Niskanen et al. [7], one was
GAD-antibody-negative. This was the only other case we
found in the literature of absolute insulin deficiency con-
firmed using sSCP in non-autoimmune Type 2 diabetes [7].
It is possible that the cross-sectional measurement of pancre-
atic autoantibodies in our study may have missed some
patients who were antibody-positive at an earlier stage, but
lost this positivity over time; however, numerous studies have
found that high GAD titres persist [7,9,19,20]. The cross-
sectional design of the present study meant we were able to
look a wide range of durations of diabetes, longer than those
looked at before in Type 2 diabetes, and this may help explain
why we have detected absolute insulin deficiency where
others have not. No previous studies we have found were
designed to look for absolute insulin deficiency in Type 2
diabetes; the majority have looked at the significance of GAD
antibodies on the deterioration in b-cell function over time.
Urinary C-peptide creatinine ratio testing
The urinary C-peptide creatinine ratio was used in this study
as a practical test in a large number of individuals, and was
able to detect patients at risk of absolute insulin deficiency.
The gold standard MMTT was used to confirm findings.
Those with evidence of endogenous insulin secretion on an
initial UCPCR test had consistent results, both on repeat
UCPCR and on MMTT. As would be expected by regression
to the mean when selecting a low cut-off, those with an
initial low UCPCR suggesting absolute insulin deficiency had
a tendency to higher results upon repeat testing, taking some
above the designated 0.2 nmol/mmol threshold. In addition,
some practical issues were identified which may have led to
erroneously low UCPCR results on initial testing: these
included patients tipping out the boric acid preservative from
the sample pots, and postal delays. Additionally, in those
with low endogenous insulin levels, variation in meal
stimulus may have contributed to a low UCPCR on one
occasion vs. a UCPCR over the 0.2 nmol/mmol threshold on
another occasion. This is supported by the finding that, in
four patients, despite two home UCPCR results suggestive of
absolute insulin deficiency, a higher UCPCR and measurable
(though low) sSCP levels were seen under controlled MMTT
conditions. This suggests the MMTT was more stimulating
than the home meals of these patients and they were still able
to mount an insulin response when maximally stimulated.
Nevertheless, insulin secretion with their normal diet may be
more clinically relevant.
The screening method did identify individuals with genu-
ine absolute insulin deficiency. With clear instructions on
how optimally to take a sample for UCPCR testing, and
advice to repeat a low UCPCR in the first instance, it is a very
easy and practical test which has the advantage of being
widely available, avoiding the need for venepuncture, and
being able be carried out at home and posted in. Since the
completion of the present study, it has been shown that the
previously widely perceived practical limitations in measure-
ment of C-peptide in blood may be to some extent overcome
by using ethylenediaminetetraacetic acid (EDTA) sample
tubes: these can improve the stability of C-peptide concen-
trations to > 24 h at room temperature (average 19.5C)
[21]. This would also make measurement of C-peptide in
blood a viable test in the outpatient/primary care setting.
In the increasingly complex climate of diabetes manage-
ment options, confirmation (or not) of insulin deficiency
should help guide treatment, education and management
decisions, which will be valuable in optimizing care for any
patient, but perhaps particularly for the more frail, older
patient. We would suggest that a measure of C-peptide, such
as UCPCR, may have an important role when clinical
features, such as marked variation in blood glucose values,
suggest absolute insulin deficiency.
Clinical characteristics
In our study, those with confirmed absolute insulin deficiency
had started insulin sooner after diagnosis than those with
retained endogenous insulin (2.5 vs. 6 years), and had lower
BMIs (25 vs. 29 kg/m2). In terms of other easily available
and measurable baseline patient characteristics, there was
little else to distinguish them.
Although two of the five patients with confirmed absolute
insulin deficiency were on basal-bolus regimens, the three
others, and several of those with low endogenous insulin
levels, were on unusual regimens more suited to patients with
endogenous insulin secretion. Two of the five were still on
oral hypoglycaemic agents, and none had had any training,
such as the DAFNE course [12], to help them understand and
manage their diabetes better.
Theoretically despite a clinical diagnosis of Type 2
diabetes, patients with absolute insulin deficiency may be at
risk of the complications seen in Type 1 diabetes. This was
reflected in all of the patients with absolute insulin deficiency
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– and those with low endogenous insulin levels - reporting
difficulty in managing their blood glucose levels owing to
seemingly unpredictable fluctuations in blood glucose levels,
and one patient having had an episode of ketoacidosis.
Implications for clinical practice
Identification of absolute insulin deficiency in patients with a
clinical diagnosis of Type 2 diabetes may enable optimization
of their treatment such as basal-bolus regimens, management
and education such as DAFNE courses [12], and recognition
of potential complications such as higher risks of hypoglyca-
emia or ketoacidosis. All these have not been traditional
considerations in many patients with Type 2 diabetes, and
recognition should help improve the quality of life of these
individuals.
The UCPCR is a practical and useful test to detect
absolute insulin deficiency in Type 2 diabetes and should be
used in individuals with Type 2 diabetes developing
ketoacidosis, severe hypoglycaemia or having a large fluc-
tuation in blood glucose values, to help inform optimum
diagnosis and/or management. A UCPCR suggestive of
endogenous insulin production is reliable, and in this clinical
context may suggest other explanations for the clinical
features (such as compliance). A low UCPCR suggestive of
insulin deficiency should be repeated in the first instance, but
may help guide management and education as described
above.
Conclusion
In conclusion, we have shown that absolute insulin deficiency
is present in 3% of insulin-treated subjects with Type 2
diabetes and may be detected using UCPCR. Clinical features
such as GAD antibodies, starting insulin sooner after
diagnosis, and having a lower BMI are pointers to help
recognize those at risk, but are not diagnostic. Those with
absolute insulin deficiency are at risk of more fluctuant blood
glucose levels, hypoglycaemia and ketoacidosis, which may
adversely affect quality of life as well as potentially have
more severe consequences, especially in the older population.
Recognition of absolute insulin deficiency is thus important
as it will aid the optimum management of these individuals,
and the UCPCR is a useful test that can be used in general
practice or in outpatients to confirm a clinical suspicion of
insulin deficiency.
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